3 results
Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…
Primary: 1/ To determine the higher of the tolerated dose of INC280 tablets with food between 300 and 400 mg BID in patients with cMET dysregulated advanced solid tumors. 2/ To assess the PK of INC280 with food.Secondary: To assess the safety of…
Primary Objective• To evaluate the effect of EDP-938 on the progression of RSV infection by assessment of clinical symptomsSecondary Objectives• To evaluate the antiviral efficacy of EDP-938• To evaluate the pharmacokinetics (PK) of EDP-938• To…